Respiratory failure due to achalasia cardia  by Ali, Hakim Azfar et al.
Respiratory Medicine CME (2009) 2, 40e43CASE REPORT
Respiratory failure due to achalasia cardiaHakim Azfar Ali a,*, Ganesan Murali a, Berjees Mukhtar ba Division of Pulmonary and Critical Care, Albert Einstein Medical Center, Suite 331 Klein, 5401 Old York Road,
Philadelphia, PA 19141, USA
b Department of Internal Medicine, Albert Einstein Medical Center, Suite 331 Klein, 5401 Old York Road,
Philadelphia, PA 19141, USA
Received 29 February 2008; accepted 4 March 2008KEYWORDS
Achalasia;
Respiratory failure;
Aspiration;
Pneumonitis;
Pseudoachalasia;
Botulinum* Corresponding author. Tel.: þ913
66951; fax: þ1 2154561766.
E-mail address: alih@einstein.edu
1755-0017/$34 ª 2008 Published by E
doi:10.1016/j.rmedc.2008.03.010Summary
A 76-year-old male was seen in our hospital for hypoxic respiratory failure and bronchorrhea
worsening over a few weeks. He failed treatment with antibiotics and diuretics. A CT scan
of the chest was performed which revealed a dilated esophagus with an air-fluid level with
evidence of aspiration. A contrasted upper GI series revealed typical ‘‘birds beak’’ appearance
of achalasia. He was treated with botulinum injections into lower esophageal sphincter and his
hypoxemia resolved. Achalasia is a lesser known cause of aspiration which can lead to respira-
tory failure. We have discussed the wide spectrum of aspiration syndromes seen in the setting
of various swallowing disorders.
ª 2008 Published by Elsevier Ltd.Presentation
A 76-year-old male nursing home resident was sent to our
hospital for evaluation of hypoxia and 3-week history of
cough with production of large volumes of whitish frothy
sputum. The patient a lifelong non-smoker was noted to
have resting oxygen saturation ranging from 85% to 92% for
the last 1e2 weeks. He had received azithromycin for 5
days without benefit. He denied any fever, hemoptysis,
chest pain or dysphagia. He had lost about 7 pounds over 3485 0354 (mobile), þ1 21545
(H.A. Ali).
lsevier Ltd.months and was reported to be a ‘‘slow eater’’. His past
history included a stroke with no residual deficits, epilepsy
that was well controlled and schizophrenia. His medications
included topiramate, escitalopram, quetiapine, phenytoin
and omeprazole.
Assessment
On examination he was alert and oriented. He appeared
comfortable at rest breathing at 20/min. Other vitals were
normal. Frothy whitish sputum could be visualized in his
oro-pharynx. His jugular venous pressure was normal. On
auscultation, he had bilateral crackles at the lung bases.
Bilateral pedal edema was noted. The remainder of his
examination was unremarkable.
Figure 2 Contrasted upper gastro-intestinal (GI) series
showing a dilated esophagus with tapering of the column of
barium into a typical ‘‘birds beak’’ at the gastroesophageal
junction.
An elderly male with dyspnea, frothy sputum and hypoxia 41His laboratory values included a WBC count of 8000/
mm3, hemoglobin of 12.7 g/dl, a normal basal metabolic
panel, and an albumin of 3 g/dl. The initial chest radio-
graph revealed prominence of interstitial markings.
He was given a 40 mg of IV furosemide in the ER with no
improvement. His oxygenation worsened requiring a FiO2 of
50% over next 24 h. A CT scan of the chest revealed diffuse
dilatation of the esophagus containing an air-fluid level
without apparent wall thickening or point of obstruction
(Fig. 1). The lung parenchyma showed a micronodular
pattern with alveolar filling at the bases consistent with
aspiration. A contrasted upper gastro-intestinal (GI) series
were ordered (Fig. 2). The esophagus appeared dilated, and
the column of barium tapered into a typical ‘‘birds beak’’
at the gastroesophageal junction, with significantly delayed
emptying. Multiple tertiary contractions were visualized.
This was consistent with achalasia.
Diagnosis
Achalasia is a primary esophageal motility disorder char-
acterized by failure of esophageal peristalsis and lower
esophageal sphincter (LES) relaxation due to damage to the
myenteric plexus. Initially described in 1674 by Sir Thomas
Williams as a disease it was first termed achalasia (Greek
for ‘‘lack of relaxation’’) by Hurst in 1927.Achalasia is
a relatively rare disease affecting the genders equally with
a prevalence of less than 1/10,000 and an incidence
between 0.03 and 1/100,000 per year. The peak incidence
is seen in the 3rd and 7th decade of life.1
Achalasia can be classified as primary when a direct
etiology cannot be identified or secondary when there is
a well-defined cause like Chagas disease. In either type,
the pathogenesis involves degeneration of the plexus
myentericus resulting in a lack of inhibitory impulsesFigure 1 CT scan of the chest showing a dilated esophagus
containing an air-fluid level with micronodular infiltrates in the
pulmonary parenchyma.needed for coordination of lower esophageal sphincter
relaxation and esophageal peristalsis.2 This may have
a genetic, autoimmune or infectious (viral) origin but the
exact cause remains to be determined.
The usual clinical presentation is that of progressive
dysphagia both for liquids and solids, regurgitation and
chest pain. Symptoms can often be misinterpreted as
gastroesophageal reflux disease leading to delayed diag-
nosis typically by 2e3 years. Symptoms may be worse in
recumbent posture. More subtle symptoms include an
increase in the time spent in eating (upon questioning). In
patients with recent dysphagia (<6 months), weight loss
and age >50 years, pseudoachalasia secondary to
a neoplasm should be ruled out by endoscopy and a CT scan.
Clinical symptoms related to aspiration have been well
recognized in patients with achalasia. There is a strong
association between dysphagia, esophageal disorders
(Table 1) and the development of complications of aspira-
tion.3 This is most likely secondary to the change in volume
and frequency and bacteriology of the secretions.
Several acute or chronic pulmonary syndromes (Table 2)
may occur after aspiration, depending on the amount and
nature of the aspirated material, the frequency ofTable 1 Esophageal disorders associated with pulmonary
aspiration.
1. Achalasia cardia(primary or secondary)
2. Scleroderma
3. Esophageal/pharyngeal diverticula
4. Esophageal neoplasia
5. Gastroesophageal reflux
6. Hiatal hernia
Table 2 Pulmonary aspiration syndromes.
Acute aspiration pneumonitis
Acute aspiration pneumonia
Chronic aspiration pneumonitis
Diffuse aspiration bronchioloitis
Isolated bronchospasm
Airway obstruction
Lung abscess
Exogenous lipoid pneumonia
Chronic interstitial fibrosis
Atypical mycobacterial infections (M. fortuitum).
42 H.A. Ali et al.aspiration, and the host’s response to the aspirate. The
most well recognized is chemical injury from the acid
contents of the stomach leading to a lung injury pattern
termed aspiration pneumonitis, usually self-limited.4
The aspirate may be colonized bacteria that can lead to
aspiration pneumonia in the right setting. The recognition
of the different syndromes associated with aspiration is
important to prevent inappropriate antibiotic use. The
distinction between a pneumonitis and pneumonia is
primarily clinical. A pneumonia presents with persistent or
worsening clinical and radiological picture beyond 48 h
after aspiration. The majority of reports describe dyspnea
with patchy bilateral alveolar opacities.
Atypical mycobacteria particularly Mycobacterium for-
tuitum can cause disease in the setting of dysphagia.5
The mechanical effects of a large food bolus may lead to
bronchial obstruction and atelectasis.
Any of the syndromes associated with aspiration may
present with similar pulmonary symptoms including recur-
rent wheezing, apnea, chronic cough, bronchorrhea,
hypoxemia and refractory asthma. Bronchorrhea is defined
as the production of more than 100 ml per day of watery
sputum. Bronchorrhea may occur in either bronchioloalveo-
lar or metastatic cancer growing in a bronchioloalveolar
pattern and has been reported with aspiration.
A long term or recurrent aspiration can lead to chronic
interstitial changes/fibrosis clinically represented as inter-
mittent cough and waxing and waning pulmonary lesions.
The term diffuse alveolar bronchiolitis (DAB) has been
proposed to define a clinical entity that is characterized by
a chronic inflammation of bronchioles caused by recurrent
aspiration of foreign bodies.6 DAB was originally recognized
in the elderly, but can occur in younger patients with
achalasia or GERD with similar manifestations.
Esophageal manometry is the gold standard to diagnose
achalasia. It classically reveals esophageal aperistalsis with
a non-relaxing lower esophageal sphincter (LES) with pres-
sures frequently above 8 mmHg.7 Typical radiographic find-
ings on a barium swallow study include the smooth tapering
in the distal esophagus with the typical ‘‘birds beak’’ or
‘‘champagne glass’’ appearance proximal dilatation and lack
of primary peristalsis noticed during fluoroscopy.
Management
An upper gastro-intestinal endoscopy did not reveal mucosal
abnormalities or endo-luminal lesions. 100 units of botulinum
toxinwere injected sequentially in 5 different locations. Overthe next few days, the patients’ diet was advanced, his
oxygen requirements improvedandhewasdischargedback to
the nursing homewith 2 l of oxygen and outpatient follow-up.
The treatment of pulmonary aspiration in the setting of
achalasia includes management of the pulmonary issues
and treatment of achalasia. Antibiotics are not routinely
indicated in aspiration pneumonitis but are the mainstay of
treatment in aspiration pneumonia. Empirical therapy
with broad-spectrum agents is recommended. Anaerobic
coverage is not routinely indicated. Sampling of the lower
respiratory tract for culture may allow targeted antibiotic
therapy and subsequent de-escalation. All cases need
supportive care with oxygen and support of ventilation with
decompensation. Preventive measures for further episodes
of aspiration include treatment of the underlying condition
and in the case of critically ill or nursing home patients’
elevation of the head of bed.
Medical therapy such as calcium channel blockers,
nitrates and phosophodiesterase inhibitors aimed at
reducing lower esophageal sphincter pressure is usually
ineffective. Patients who are good surgical candidates
should be offered either pneumatic balloon dilatation or
laparoscopic myotomy. Long term (i.e. 5e10 years) clinical
response rates to balloon dilatations range from 40% to
80%.8 Symptom improvement after myotomy ranges from
83% to 100% for the first year and 67e85% for sustained (i.e.
>10 years) remission.9
In the only randomized trial comparing outcomes 95% of
patients treatedwith surgicalmyotomyhad a good long-term
result comparedwith 65%of patients treatedwith pneumatic
dilatation10 with lower risk of subsequent interventions.
If there are contraindications to surgery the patients
can be offered endoscopic injection of botulinum toxin A
(botox) in the lower esophageal sphincter which that acts
by presynaptic cholinergic blockade. The best results
have been noticed in patients with vigorous achalasia.
Although the majority of patients notice important
improvement after the first treatment, patients should be
followed up regularly in order to identify disease
progression early and avoid the development of the end-
stage disease when esophagectomy may become the only
treatment option.
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